$22.87
3.23% yesterday
NYSE, Nov 03, 10:00 pm CET
ISIN
US28414H1032
Symbol
ELAN

Elanco Animal Health, Inc. Stock price

$22.85
+2.21 10.71% 1M
+13.20 136.79% 6M
+10.74 88.69% YTD
+10.29 81.93% 1Y
+9.99 77.68% 3Y
-8.39 26.86% 5Y
-13.15 36.53% 10Y
-13.15 36.53% 20Y
NYSE, Closing price Mon, Nov 03 2025
+0.70 3.16%
ISIN
US28414H1032
Symbol
ELAN
Industry

Key metrics

Basic
Market capitalization
$11.4b
Enterprise Value
$15.0b
Net debt
$3.7b
Cash
$539.0m
Shares outstanding
496.7m
Valuation (TTM | estimate)
P/E
26.3 | 24.8
P/S
2.5 | 2.4
EV/Sales
3.4 | 3.2
EV/FCF
43.3
P/B
1.7
Financial Health
Equity Ratio
48.3%
Return on Equity
5.5%
ROCE
1.7%
ROIC
1.3%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$4.5b | $4.7b
EBITDA
$736.0m | $900.0m
EBIT
$209.0m | $678.2m
Net Income
$434.0m | $457.7m
Free Cash Flow
$347.0m
Growth (TTM | estimate)
Revenue
-0.2% | 5.7%
EBITDA
-12.6% | 15.7%
EBIT
-30.3% | 170.2%
Net Income
134.6% | 35.4%
Free Cash Flow
-18.4%
Margin (TTM | estimate)
Gross
54.7%
EBITDA
16.4% | 19.2%
EBIT
4.7%
Net
9.7% | 9.8%
Free Cash Flow
7.7%
More
EPS
$0.9
FCF per Share
$0.7
Short interest
6.9%
Employees
9k
Rev per Employee
$480.0k
Show more

Is Elanco Animal Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Elanco Animal Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Elanco Animal Health, Inc. forecast:

16x Buy
76%
5x Hold
24%

Analyst Opinions

21 Analysts have issued a Elanco Animal Health, Inc. forecast:

Buy
76%
Hold
24%

Financial data from Elanco Animal Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,484 4,484
0% 0%
100%
- Direct Costs 2,030 2,030
1% 1%
45%
2,454 2,454
1% 1%
55%
- Selling and Administrative Expenses 1,364 1,364
5% 5%
30%
- Research and Development Expense 354 354
4% 4%
8%
736 736
13% 13%
16%
- Depreciation and Amortization 527 527
3% 3%
12%
EBIT (Operating Income) EBIT 209 209
30% 30%
5%
Net Profit 434 434
135% 135%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Elanco Animal Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Elanco Animal Health, Inc. Stock News

Neutral
PRNewsWire
8 days ago
FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-legged ticks (lxodes scapularis) and protection against the longhorned tick (Haemaphysalis longicornis), which is rapidly spreading, now reaching 22 states.i  The Companion Animal and Parasite Council tracker shows more than 422,000 cases of Lyme disease in dogs so far t...
Positive
Reuters
10 days ago
Elanco Animal Health said on Friday it had received an emergency use authorization from the U.S. Food and Drug Administration for its flea and tick drug to treat dogs infected with a flesh-eating parasite found near the U.S.-Mexico border.
Positive
WSJ
10 days ago
Health and Human Services Secretary Robert F. Kennedy Jr. determined that New World screwworm presents significant potential for a public health emergency.
More Elanco Animal Health, Inc. News

Company Profile

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Head office United States
CEO Jeffrey Simmons
Employees 9,225
Founded 1954
Website www.elanco.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today